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Purpose: Extracellular vesicles (EVs) are small,
membrane-enclosed entities released from cells in
many different biological systems. These vesicles play
an important role in cellular communication by virtue
of their protein, RNA, and lipid content, which can be
transferred among cells. The complement of biomole-
cules reﬂects the parent cell, and their characterization
may provide information about the presence of an
aberrant process. Peripheral blood is a rich source of
circulating EVs, which are easily accessible through a
blood sample. An analysis of EVs in peripheral blood
could provide access to unparalleled amounts of
biomarkers of great diagnostic and prognostic value.
The objectives of this review are to brieﬂy present the
current knowledge about EVs and to introduce a
toolbox of selected techniques, which can be used to
rapidly characterize clinically relevant properties of
EVs from peripheral blood.
Methods: Several techniques exist to characterize
the different features of EVs, including size, enumer-
ation, RNA cargo, and protein phenotype. Each
technique has a number of advantages and pitfalls.
However, with the techniques presented in this review,
a possible platform for EV characterization in a
clinical setting is outlined.
Findings: Although EVs have great diagnostic and
prognostic potential, a lack of standardization regard-
ing EV analysis hampers the full use of this potential.Accepted for publication May 15, 2014.
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830Nevertheless, the analysis of EVs in peripheral blood
has several advantages compared with traditional
analyses of many soluble molecules in blood.
Implications: Overall, the use of EV analysis as a
diagnostic and prognostic tool has prodigious clinical
potential. (Clin Ther. 2014;36:830–846) & 2014 The
Authors. Published by Elsevier HS Journals, Inc.
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enumeration.INTRODUCTION
In recent years, interest in the characterization, bio-
genesis, and function of extracellular vesicles (EVs)
has increased immensely. These membrane-derived
vesicles play vital roles in a plethora of processes in
several biological systems. In humans, EVs are pivotal
to cellular communication for the maintenance of
homeostasis and the development and progression of
pathologic conditions, such as cancer. Consequently,
this communication forms the basis for the use of EV
analysis in a clinical setting because EVs seem to be a
promising source of biomarkers of diagnostic and
prognostic value. EV analysis can likely be used as one
component of treatment surveillance. In addition, EVs
have the potential of being used as drug therapy
entities, delivering a tailored pharmacologic cargo to
a speciﬁc target.Scan the QR Code with your phone to obtain
FREE ACCESS to the articles featured in the
Clinical Therapeutics topical updates or text
GS2C65 to 64842. To scan QR Codes your
phone must have a QR Code reader installed.
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In general, EVs are a heterogeneous population of
membrane-enclosed vesicles released from a variety of
cells into the extracellular space in vivo and in vitro.
One general feature for these vesicles is that they are
enclosed by a membrane that consists of a phospholi-
pid bilayer. However, the EVs can be divided into a
number of subpopulations each with speciﬁc character-
istics, including their biogenesis, size, cellular origin,
protein composition, mRNA and microRNA (miRNA)
content, and/or biological function. With biogenesis as
a classiﬁcation tool, the EVs can be divided into 3
major groups: exosomes, microvesicles (MVs), and
apoptotic bodies. Many of the properties of EVs, and
in particular exosomes, have been reviewed extensively
elsewhere1–9; therefore, the following section states the
overall characteristics of these 3 EV groups.
Exosomes
Exosome is the vesicle type that has been studied most
intensely. They are approximately 30 to 100 nm in
diameter and originate from inward budding of the
limiting membrane of multivesicular bodies, which are
late endosomal compartments present in the cytosol of
the cell.4,6,10,11 When the multivesicular bodies fuse with
the plasma membrane, the release of the exosomes to the
extracellular space is facilitated. The biogenesis of the
exosomes causes the orientation of the membrane pro-
teins to be similar to that of the plasma membrane. The
exosomal membrane is enriched in cholesterol, ceramide,
and sphingomyelin and exposes the phospholipid phos-
phatidylserine.6,11 In addition, exosomes contain several
proteins that are currently used as markers to identify
exosomes. These makers are not ubiquitously expressed
on all exosomes but are found in a large proportion of
these vesicles. Therefore, they are generally accepted as
exosomal markers. These markers include TSG101, Alix,
and the tetraspanins CD9, CD63, and CD81.2,4 Along
with these hallmark proteins, the phenotype of exosomes
often reﬂects a molecular signature of the cell from which
they originate. This cell-speciﬁc signature may provide
some indication about the functionality of the exosomes
because some of these signature molecules could ensure
the delivery of the exosomes to the correct target cell,12
point to a signal being transduced by a receptor-ligand
interaction of exosomes and recipient cell,13 or simply
indicate which cells are the active exosome producers.14
The composition of the exosome cargo can also be
related to the potential biological function of this vesicleJune 2014type. They have been known to contain proteins from
both the plasma membrane and cytosol along with
mRNA and the non–protein-coding miRNAs and small
interfering RNAs.2,15–17
Microvesicles
The size of MVs ranges from 100 to 1000 nm. They
are formed from outward budding of the plasma
membrane, thus releasing the MVs directly into the
extracellular space.2,4,18 Hence, the membrane proteins
of MVs retain the topologic features of those found in
the plasma membrane. Generally, most MVs incorpo-
rate phosphatidylserine in the outer leaﬂet of the
membrane.4,6,10,19 This feature has frequently been used
to isolate and identify MVs from biological samples
along with a combination of cell-speciﬁc protein
markers to determine their cellular origin.19,20 How-
ever, several studies indicate that phosphatidylserine
may only be present in some subpopulations of MVs.21–24
Currently, there is a less extensive list of markers to
identify MVs when compared with exosomes. Nonethe-
less, CD40 ligand, adenosine diphosphate ribosylation
factor 6, and several integrins and selectins have been
proposed as MV markers.2,5,6,18,25 Like exosomes, the
phenotype of MVs reﬂects their parent cell, and the
content of the vesicle cargo also includes membrane and
cytosolic proteins, mRNA, and miRNAs.2,5
Apoptotic Bodies
Apoptotic bodies are the largest vesicle type of the 3
major EV classiﬁcation groups, with a size ranging from
approximately 500 to 4000 nm.26,27 They are formed
from blebbing of the plasma membrane in cells under-
going apoptosis, releasing the apoptotic bodies straight
into the extracellular space.4 Similar to both the
membrane of exosomes and MVs, phosphatidylserine
can be found in the outer leaﬂet of the lipid bilayer of
apoptotic bodies.2,6,10,28 In terms of identifying apop-
totic bodies, thrombospondin and complement compo-
nent C3b are in many cases accepted apoptotic body
markers.1 Unlike the 2 other vesicle types, apoptotic
bodies are distinguished by containing organelles, DNA
fragments, and histones as a part of the vesicular cargo
in addition to proteins and other molecules from the
cytosol of the parent cell.2,4,27,28
EVs and the Immune System
Because some of the ﬁrst reports of vesicular
release were published 3 decades ago,29,30 an831
Clinical Therapeuticsenormous amount of research has been performed to
delineate all aspects of this phenomenon, however,
predominantly related to exosomes and MVs. Within
the ﬁeld of immunology, the evidence of the immuno-
modulatory effects of EVs has steadily increased through-
out the years. Several studies document that many of the
cells of the adaptive and innate immune system release
EVs, including T and B lymphocytes, dendritic cells, and
mast cells.12,15,31–33 Exosomes have in particular been
implicated in several contexts of antigen presentation. T
cells can be activated by major histocompatibility com-
plex II–bearing exosomes from antigen-presenting cells,12
and some T cells even acquire these major histocompa-
tibility complex II molecules,34 enabling them to present
antigens to other T cells.13 On the transcriptional level,
miRNA can also be transferred from T cells to antigen-
presenting cells by exosomes, and this molecular transfer
changes the gene expression of the recipient cell.13 In
relation to pathologic challenges of the immune system,
EVs have been associated with the spread of several types
of infection. Accordingly, EVs from cells infected with
HIV-1, Epstein-Barr virus, hepatitis C virus, and cyto-
megalovirus mediate the spread of these pathogens by
entering the recipient cell.35,36 In addition, EVs from
infected cells can help initiate a proper immune response
against the pathogen.37 Numerous studies have found
that tumor-derived EVs can exert immunosuppressive
functions, thus promoting tumor progression.38 This can
be facilitated by modulation of T cells, including the
inhibition of both function and proliferation of anti–
tumor-speciﬁc T cells39 or by promotion of suppressive
subsets of T cells.40,41 Tumor-derived EVs can also play
a role in transferring oncogenic activity, as was observed
with the vesicular transfer of the oncogenic epidermal
growth factor receptor vIII from glioma cells.42 This
receptor could also be detected on tumor EVs in serum
from a number of patients with glioblastoma.17
Currently, it is apparent that several aspects of the
mechanisms and functional consequences of EVs have
yet to be determined. Nonetheless, it is also evident from
the work already performed that EVs are central to an
abundance of cellular processes, including those of a
pathologic nature, and consequently have great potential
as targets for diagnosis, prognosis, or treatment.
DIAGNOSTIC AND PROGNOSTIC POTENTIAL
OF EVs IN PERIPHERAL BLOOD
Numerous studies have established that EVs can be
detected in a multitude of biological ﬂuids, such as832saliva, urine, blood, ascites, breast milk, and cerebro-
spinal ﬂuid.1,8,9 In this context, blood is an immense
source of EVs, and serum is estimated to contain
approximately 3  106 exosomes per microliter.8
Because EVs are released constitutively into the
bloodstream and this release increases on cellular
activation, as well as in many pathologic condi-
tions,43–46 a mere enumeration of EVs may indicate
the presence of an aberrant process. In many aspects
of diagnostics, the use of blood samples is already
implemented in the clinic because it is known that
blood harbors a vast amount of biomarkers and other
biologically relevant molecules. In addition, most
tissues will contribute to this molecular reservoir due
to dense vascularization of the body. In line with this,
the analysis of EVs in peripheral blood is likely to
provide an indicator of the systemic health status,
which can be used in clinical settings.
Analysis of EVs in Peripheral Blood
The use of EV analysis encompasses several advan-
tages over the traditional analyses of many soluble
molecules in blood, such as hormones and cytokines.
One signiﬁcant advantage is the inherent protection of
the EV cargo of proteins and RNA from degradation,
thus rendering them intact and functional.17 Other-
wise, they would be rapidly degraded in blood.8 This
has proven to be particularly signiﬁcant for the use of
miRNA as valuable biomarkers because most RNA in
blood exists as cargo of EVs. Regarding another
aspect of stability, EVs appear to have a relatively
long half-life in blood.8 Therefore, EVs can likely be
transported from any location of the body to the
bloodstream, thus making them easily accessible for
analysis, compared with biopsies. This also has a
signiﬁcant advantage for the patient because the
collection of a blood sample is a minimally invasive
procedure associated with much less discomfort than a
biopsy. Another advantage of EVs links to the great
dynamic range of molecules present in the blood-
stream. It can often become an issue to detect relevant
biomarkers because these diagnostic molecules
frequently constitute a small part of the total
amount of molecules in a blood sample.47,48 This is
also the case for EV-associated proteins, which for
exosomes denote o0.01% of the plasma proteome.9
However, on the basis of the presence of a relatively
small panel of markers, EVs can be identiﬁed, and
the phenotype and cargo, holding biomarkers ofVolume 36 Number 6
Table I. miRNAs differentially expressed pathologic
conditions.
miRNA Cancer Type Reference
miR-1 NSCLC 51
miR-15b Melanoma 52
miR-17-3p Colorectal cancer 53
miR-21 DLBCL 54
Glioblastoma 17
Ovarian cancer 55
miR-25 NSCLC 56
miR-30d NSCLC 51
miR-92 Colorectal cancer 53
Ovarian cancer 55
miR-93 Ovarian cancer 55
miR-141 Prostate cancer 57
miR-155 DLBCL 54
Breast cancer 58
miR-182 Melanoma 59
miR-210 DLBCL 54
miR-223 NSCLC 56
miR-486 NSCLC 51
miR-499 NSCLC 51
DLBCL ¼ diffuse large B-cell lymphoma; miRNA ¼
micro-RNA; NSCLC ¼ non–small cell lung cancer.
A.L.S. Revenfeld et al.otherwise undetectable amounts, can be analyzed and
interpreted into clinically relevant information. Further-
more, EV size distribution, phenotype, or cargo content
can seemingly change according to the progression of a
disease.43–46,49,50 The access to cell-speciﬁc and disease
state–speciﬁc EV proﬁles of proteins and RNA from a
blood sample renders a sophisticated ﬁngerprint of a
disease of diagnostic and prognostic value.
EV Analysis in Risk Stratification
Cases are emerging in which EV analyses of blood
samples seem to be good candidates as a part of a
diagnostic platform. In addition, some examples exist in
which this type of analysis shows a promising prog-
nostic potential. As previously mentioned, the number
of detectable EVs in a blood sample seems to increase in
several types of cancers compared with healthy individ-
uals.43–46,49,50 Moreover, in some cases the amount of
EVs continuously increase as the disease progresses into
later stages.44,45 In further relation to cancer, protein
and RNA biomarkers have been identiﬁed in EVs from
the peripheral circulation, with the preponderance of
cases that involve miRNAs found in exosomes. Accord-
ingly, several cases reveal that either a single or a panel
of differentially expressed miRNAs can signiﬁcantly
identify patients with cancer compared with control
individuals.46,50 A selected number of EV miRNAs,
which have the potential to become biomarkers of
several cancer types, are given in Table I.
The use of EV protein markers in risk stratiﬁcation
has also been investigated. One study found that the
presence of 2 exosomal proteins in exosomes from
plasma distinguished patients with ovarian cancer
from controls.43 In another study, EVs from patients
with gastric cancer had signiﬁcantly increased
expression of 2 proteins, including HER2/neu, when
compared with controls.44 From this study, an
interesting notion arises, indicating that some EV
markers may not exclusively be used in diagnosis
but could also indicate which patients are eligible for a
speciﬁc treatment. A list of disease-related EV proteins
from blood is given in Table II.
CHARACTERIZATION OF EVs IN
PERIPHERAL BLOOD
The characterization of EVs in peripheral blood can
be based on several of their biochemical and biophys-
ical properties. These properties include size, cargo,
density, morphologic ﬁndings, lipid composition, andJune 2014protein phenotype. Currently, a wide range of techni-
ques facilitates EV analysis. Some techniques have
existed for years and are being further developed to
embrace the challenges of this type of analysis. Other
techniques have emerged as a consequence of the
increasing interest within the ﬁeld. The focus of the
following section is to introduce a toolbox of selected
techniques that could be part of a potential platform
to rapidly characterize several clinically relevant prop-
erties of EVs in peripheral blood. An overview of the
steps from blood sample to output of the analysis will
be presented for each technique along with advantages
and pitfalls. A summary of several key features
associated with the presented techniques is outlined
in Figure 1.Isolation of EVs From Peripheral Blood
One aspect that is a prerequisite for almost all
techniques used for EV analysis is isolation of EVs833
Table II. Selected protein extracellular vesicle markers isolated from blood.
Disease Markers Reference
Ovarian cancer L1CAM, CD24, ADAM10, EMMPRIN 60
TGFβ1, MAGE3/6 43
Claudin-4 49
Glioblastoma EGFRvIII 17
EGFR, EGFRvIII, PDPN, IDH1 61
Melanoma CD63 and Caveolin 1 62
Oral cancer FasL 63
Gastric cancer HER-2/neu, CCR6 44
Cancer-associated thrombosis Tissue factor (CD142) 64
Alzheimer disease Amyloid B 65
Clinical Therapeuticsfrom the biological ﬂuid in which they are present.
Hence, it is evident that EV isolation is essential, and
with no standardized protocols yet, this is a major
focus in the ﬁeld of EV research.66 This section
introduces the key points of EV isolation because
many aspects of this procedure have been recently
described elsewhere.8,66–68 Currently, most studies of
EVs use differential centrifugation for isolation, some-
times accompanied by a size ﬁltration step.66,68 The
isolation includes numerous sequential centrifugation
steps with increasing centrifugal force, thus using size
and density properties of the EV subsets to separate
these from other components of blood. Initially, low-
speed steps (300-500g) are applied to remove whole
cells.43,67 This is followed by higher speeds, typically
in the range of 10,000 to 20,000g, to remove cellular
debris and to isolate larger EVs 4100 nm.43,66,68–70
Finally, one or more ultracentrifugation steps are
applied to pellet the smallest EVs, using centrifugal
forces in the range of 100,000 to 200,000g.43,66–68 It
is also possible to combine the ultracentrifugation
with a density gradient, such as sucrose or iodixa-
nol,67 or afﬁnity puriﬁcation.71 Nevertheless, the
choice of isolation procedure may have a
considerable effect on the downstream analyses of
EVs from blood. In addition to isolation, the
preanalytical procedures also encompass choice of
anticoagulant, processing temperature, and storage
before analysis. These variables are all likely to
affect the dynamic material that blood constitutes,
and although standardizations are in the pipeline,
several recommendations have been published.66834PHENOTYPING AND PROTEIN VALIDATION
Several methods exist to characterize the protein
composition of EVs, related to either a surface marker
phenotype or the proteins present in the EV cargo.
Although the EV phenotype is particularly important
in the determination of cellular and subcellular origin,
it can in combination with a protein cargo analysis
also provide clues about the functionality of the EVs.
The following section focuses on 4 techniques used for
characterization of EV proteins because they have
great potential as reliable methods used in EV analy-
sis. Common to all 4 methods is the dependence and
use of antibodies. Consequently, they all rely on the
speciﬁcity and sensitivity of the applied antibodies.
Currently, no proteins are known to be constitutively
sorted into vesicles independently of the subcellular
origin of the vesicle and the activation status of the
producing cell. This lack of invariant housekeeping
markers hampers the quantitative analysis of vesicles.
In the 1990s, exosomes derived from B cells were
discovered to contain the lysosomal membrane pro-
tein CD63,72 and later other members of the tetra-
spanin superfamily were found to be enriched in
exosomes as well.73 These early studies also found
that exosomal CD63 is present in a much lower
amount compared with that of the producing cells.
In contrast, CD81 was 410-fold up-regulated in
exosomes.73 The phenotyping of plasma exosomes
from 7 healthy donors revealed a similar tendency,
indicating that CD63 is less represented and in a
heterogeneous manner in relation to CD81 and
CD9.74 This ﬁnding could challenge the commonVolume 36 Number 6
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Figure 1. Overview of the techniques used to analyze extracellular vesicles (EVs) present in blood samples
from a clinical and diagnostic perspective. The 3 major characterization areas are illustrated
(phenotyping, size and enumeration, and RNA cargo) and the major advantages and pitfalls are
outlined for each of the techniques presented in this review. abs ¼ antibodies; cDNA ¼
complementary DNA; LOD ¼ limit of detection; F-NTA ¼ fluorescence nanoparticle tracking
analysis; micro-NMR ¼ micro–nuclear magnetic resonance; MVs ¼ microvesicles; NTA ¼
nanoparticle tracking analysis; qRT-PCR ¼ quantitative real-time reverse transcription–polymerase
chain reaction; SIOS ¼ scanning ion occlusion sensing.
A.L.S. Revenfeld et al.perception of CD63 as an optimal exosomal
marker,72 which may have been attributed solely to
its initial discovery and description. Consequently, it is
important to choose the markers for EV phenotyping
carefully.
Western Blotting
The analytical technique called Western blotting
(WB) or immunoblotting is a widely accepted method
used to detect speciﬁc protein markers in EVs. InJune 2014general, WB is applied to validate the presence or
absence of EV protein markers in puriﬁed samples
based on the availability of speciﬁc antibodies.75–80. A
major advantage of WB is the possibility of detecting
intravesicular and membrane-associated proteins with
the same technology (Figure 1). The basic principle of
WB81–83 is outlined in Figure 2A. The results obtained
by WB are semiquantitative and can be correlated
to the presence of a uniformly expressed protein.
Multiple steps of centrifugation of the EV-containing835
Clinical Therapeuticssamples are generally needed before analysis.71,80,84 In
addition, the amount of EV-containing sample used
for WB can vary greatly. To illustrate this, it was
possible to generate 5 WBs using an EV sample of 200
mL of plasma,84 whereas another study used WB
analysis for the detection of CD63 in EVs and was
able to accomplish this with approximately 0.2 mg of
EV protein, equivalent to 108 EVs.61 Because WB
depends on a high protein concentration, sample
preparation with ultracentrifugation is needed,
which may be difﬁcult in many clinical laboratories.
Nonetheless, if the diagnostic or prognostic marker is
of intravesicular origin, WB remains the only usable
detection method of those currently applied.
Flow Cytometry
Flow cytometry is a powerful technique for multi-
parametric analysis of single biological particles and
remains the most extensively used technique for
enumeration and phenotyping of EVs in clinical
samples.85–90 By suspending particles in a hydrody-
namically focused ﬂuid stream passing a laser beam,
this technique allows simultaneous analysis of the
physical characteristics, including size and granularity,
and expression of multiple antigens of up to thou-
sands of particles per second.91,92 Different ap-
proaches are applied when phenotyping either MVs
or exosomes by ﬂow cytometry. MVs are typically
identiﬁed as particles with a forward scatter smaller
than an internal standard that consists of approxi-
mately 1-mm beads.93 Figure 2B illustrates how MVs
can be distinguished using a blend of size-calibrated
ﬂuorescent beads. When analyzing a plasma sample,
better speciﬁcity of MV detection is obtained by
identifying those MVs that expose phosphatidylserine
and cell-speciﬁc markers (Figure 2B). In addition, MV
count per analyzed volume can easily be calculated by
adding a known number of ﬂuorescent latex beads as
an internal standard. For the phenotyping of MVs by
ﬂow cytometry, use of 50 to 100 mL of platelet-free
plasma is recommended.21 Use of ﬂow cytometry to
phenotype exosomes and other EVs o200 nm
normally depends on adsorption of these vesicles
onto antibody-coated beads (Figure 2C). The beads
are large enough to facilitate the detection of these
small vesicles, which would otherwise fall below the
lower limit of detection (Figure 2C). A multi-
parametric analysis of the EVs captured onto the
beads can be performed using ﬂuorescent-labeled836antibodies against selected EV surface markers.90 To
be able to use ﬂow cytometry for plasma exosome
characterization, an isolation procedure is needed. As
an example, a 3-step centrifugation isolation on 3 mL
of plasma can be used as a preparatory procedure
before the phenotyping.89,90 The previous generation
of ﬂow cytometers is challenged by the small size and
signals from most EVs, and several laboratories have
reported that a size of 0.5 mm is the cutoff value for
accurate identiﬁcation.94 However, the enhanced
sensitivity of modern digital ﬂow cytometers allows
the detection of EVs in the range of approximately
200 nm to 1.0 mm21 (Figure 1).
Micro–Nuclear Magnetic Resonance
Micro–nuclear magnetic resonance (µ-NMR) is a
highly sensitive and rapid analytical technique devel-
oped for proﬁling circulating EVs from blood sam-
ples.61 The technique uses size and immu-
noafﬁnity to deﬁne an EV population and favors
EVs in the range of 50 to 150 nm. The EVs are
labeled with target-speciﬁc magnetic nanoparticles
and detected by a hand-sized NMR system95,96
(Figure 2D). A prototype µ-NMR system has previ-
ously been used for the detection of whole tumor cells
(target size range, 410 mm).97 The output of the
µ-NMR technique is a MV expression of an EV
protein marker, which is calculated as the decay rate
of the target protein normalized to that of a selected
exosomal marker, such as CD63.61 The output is
quantitative in a relative way across samples but
cannot be assigned a deﬁnitive number of vesicles or
number of marker molecules on each vesicle.61 Before
loading the blood sample onto the chip, a 2-step
centrifugation puriﬁcation is needed. The pelleted EVs
can be loaded onto the µ-NMR device for analysis, and
the relative contents of a single EV marker are deter-
mined within seconds. Signals are detectable to approx-
imately 104 of EVs, which is equivalent to 0.02 ng of
EV protein.61 Even if it has been established that the
expression of CD63 measured by µ-NMR correlates
with the number vesicles present,61 this may not be the
case with EVs from all cellular systems. Hence, care
should be taken to choose the appropriate exosomal
marker for normalization.
EV Array
The EV array is based on the technology of protein
microarray and is capable of detecting and phenotypingVolume 36 Number 6
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Figure 2. Outline of the workflow and timeframes for the presented techniques used for phenotyping of
extracellular vesicles (EVs) from peripheral blood. (A) Western Blotting, (B) flow cytometry of
microvesicles (MVs), (C) flow cytometry of exosomes, (D) micro–nuclear magnetic resonance (micro-
NMR), and (E) EV Array. abs ¼ antibodies; MNP ¼ magnetic nanoparticles; PS ¼ phosphatidylserine.
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Clinical TherapeuticsEVs from unpuriﬁed starting material in a high-
throughput manner.74 The technology is developed
to perform multiplexed phenotyping of EVs in an
open platform; however, it is optimized to analyze the
exosomal EV subset. Protein microarrays are well
accepted as powerful tools to search for antigens or
antibodies in various sample types.98,99 Micrometer-
sized spots of capturing antibodies against known EV
surface antigens are printed in a customized spot
setup. The basic principle of the subsequent analysis
is outlined in Figure 2E. The captured vesicles are
detected using a cocktail of antibodies against the
tetraspanins CD9, CD63 and CD81.72,78 The anti-
bodies are applied to ensure that all exosomes cap-
tured are detected, as well as excluding other types of
EVs from being detected. The read-out is a ﬂuores-
cence signal for each individual microarray spot
(Figure 2E). The method is semiquantitative and
gives the phenotype of EVs for 21 protein markers
simultaneously. Plasma samples are analyzed directly
without any further puriﬁcation or isolation steps, and
only 10 mL of plasma is needed. It has been established
that only 2.5  104 exosomes is required for each
microarray analysis.74 The technique uses an over-
night incubation to capture the EVs. Because of the
incubation time and the remaining development
procedure, this method takes approximately 2 days
to complete, making it the slowest assay of the ones
presented in this review.
ENUMERATION AND SIZE
Determination of the amount and size distribution of
EVs in a blood sample is greatly valuable because of
the previously mentioned observation that an in-
creased production of EVs has been detected in several
pathologic conditions. In addition, knowing the size of
the EVs present can be informative because it can
indicate which vesicle type is the most dominant type
in an unprocessed sample and provide information
about the quality of an isolation procedure.100 Several
methods exist to enumerate EVs and determine their
size. The following section focuses on 2 of these
because they have great potential as fast methods
used in EV analysis.
Nanoparticle Tracking Analysis
Nanoparticle tracking analysis (NTA) allows for a
quick size determination and quantiﬁcation of EVs in a
suspension. It was ﬁrst introduced in 2006 and has in838recent years received signiﬁcant attention within the
ﬁeld of EV analysis.101 The technique is based on
relating the Brownian motions of a particle to its size.
Brownian motions are experienced by all particles
in a ﬂuid, here constituted by EVs in a suspension.
These motions can be tracked when the particles are
illuminated by a laser beam and scatter the light101–103
(Figure 3A). An image processing software sub-
sequently calculates the size distribution and con-
centration of particles in the solution.100,101,104 The
NTA determines these factors most precisely for EVs in
the range of 30 to 1000 nm in a concentration of
approximately 108 to 109 particles/mL.100,102 Hence,
NTA seems to offer a more sensitive enumeration than
other conventional methods, such as ﬂow cytometry.
For the analysis of plasma, the high content of lip-
oprotein particles may pose a signiﬁcant problem.101
Consequently, it is a prerequisite to isolate the EV type
of interest before NTA, when analyzing these vesicles
from plasma or serum.101 As an interesting notion,
selected NTA instruments allow for the expansion to
ﬂuorescence NTA in which EVs can be labeled with
antibodies conjugated to stable ﬂuorophores and sub-
sequently be phenotyped in addition to the enumera-
tion and concentration determination.103
Scanning Ion Occlusion Sensing
The scanning ion occlusion sensing (SIOS) method is
a relatively new technology that facilitates a fast
analysis of EV size, concentration, and biochemical
composition. The technology is nonoptical, label free,
and based on passing each EV through a nanopore in a
membrane by means of single-molecule electrophore-
sis.105 The basic principle is shown in Figure 3B.
A transmembrane current drives the electrophoresis,
and an ionic current through the nanopore channel can
be measured.105 The passing EV shifts this current, and
the transient blockade of the pore can be translated
into information about size and surface charge.102 In
addition to the size and surface charge, the total
number of EVs passing the nanopore is detected, and
the read-out can be depicted as a plot of concentration
versus size distribution (Figure 3B). The SIOS has a
reported usability for particles in the large range of
70 nm to 10 mm and in the concentration of 105 to
1012 particles/mL.102 The use of complex samples can
pose some difﬁculties because protein aggregates
cannot be separated from MVs, which is explained
by their similar size (Figure 1). In contrast to NTA,Volume 36 Number 6
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particles analyzed because it is a nonoptical technique.
RNA CARGO
Along with the increasing attention on EVs, it has
become consistently apparent that their RNA cargo
contributes to the potential diagnostic and prognostic
value of these vesicles. As mentioned previously,
several research groups have reported that the RNA
present in serum and plasma is in fact protected from
the highly active RNases when being stored inside the
different kind of vesicles.16,57,106,107 In addition, the
major content of the EVs has been found to be small
RNAs, such as mRNA and miRNA,17,108 the latter
being small non–protein-coding pieces of RNA, con-
sisting of 18–24 nucleotides.57,109,110 They are knownJune 2014to play important roles in the regulation of mRNA,
which they can target for cleavage.109 The expression
of miRNAs seems to depend on the cellular function
and in some cases on the cellular stage. In addition, a
number of miRNAs are speciﬁc to cell type or tissue.109
As previously mentioned, a rapidly expanding list of
miRNAs as potential biomarkers is forming, in which a
differential expression can be detected between healthy
and pathologic conditions, in particular related to
cancer. A selection of such EV miRNA markers is
given in Table I. When focusing on the discovery of
potential miRNA biomarkers, approaches such as
microarray analyses and deep sequencing are useful
techniques to perform a wide search. Such a search can
be performed with pooled samples of a chosen disease
group versus a control group. After single or multiple839
Clinical Therapeuticscandidates are identiﬁed, a more targeted manner is
chosen to validate and quantify these ﬁndings to reveal
the true diagnostic potential.56 This is facilitated by
quantitative real-time reverse transcription–polymerase
chain reaction (qRT-PCR).70 Because the qRT-PCR
technique is the most relevant as a possible clinically
test to characterize the EV RNA cargo, this is the focus
of the following section.qRT-PCR
The qRT-PCR technique is based on the PCR, which is
used to amplify and simultaneously quantify a targeted
RNA molecule.111 For Z1 speciﬁc sequences in a
sample, qRT-PCR enables detection and quantiﬁcation.
The quantity can be an absolute number of copies or a
relative amount when normalized to RNA input or
additional reference genes. Initially, the characterization
of the EV RNA cargo requires extraction of the
RNA112 and complementary DNA synthesis113,114 be-
fore qRT-PCR (Figure 4). The output of the
quantiﬁcation is a signal that relates to the amount of
RNA present in the sample. Because this has no unit,
the results of the relative quantiﬁcation can be
compared across a number of different qRT-PCR
analyses. A total of Z1 reference genes are applied to
correct for nonspeciﬁc variation, such as the differences
in the quantity and quality of RNA used, which can
affect the efﬁciency of reverse transcription and there-
fore the entire PCR process. In most of the reported
work on EV RNA cargo analysis, a comprehensiveqRT-PCR
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840isolation procedure is applied (Figure 4). The isolation
often involves multiple centrifugation steps and
ﬁltration.80,115,116 However, an optimized protocol
was recently published, describing the extraction and
qRT-PCR analysis of EV RNA directly from plasma
and serum isolated with only a single centrifugation step
at low speed and time.70 Furthermore, the protocol
describes that a 250-mL sample provides a sufﬁcient
amount of RNA to perform a qRT-PCR analysis,70
which is of high value in a diagnostic relation. Other
studies conﬁrm that miRNAs can be extracted from
both serum and plasma with similar results.54,57FUTURE TECHNICAL PERSPECTIVES
The techniques presented in this review could all
potentially be part of a platform to characterize EVs
from peripheral blood and transform these data into
clinically relevant information. However, to fully
harness the diagnostic and prognostic potential of
EVs, a number of aspects remain to be delineated.
A fundamental aspect, which is imperative to address,
is standardization.66 The standardization relates to
several areas of EV analysis and research and includes
nomenclature, preanalytical conditions, and isolation
procedures. This will give rise to standardized
protocols and facilitate unbiased comparisons of
results from different studies across laboratories.
Furthermore, it will greatly aid in the development
of robust clinical assays. The next challenge, before
using EVs in a diagnostic manner, is to select the mostNA
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A.L.S. Revenfeld et al.optimal methods, concerning sample requirements,
apparatus, and analysis accessibility. In addition,
selection of the most optimal combination of target
markers is essential to several of the methods. A
common feature for all the methods outlined is the
need for an extensive isolation procedure before EV
analysis. In that regard, considerations should be
taken concerning the loss of material and thereby
valuable information. Therefore, the method of ana-
lysis should most optimally work on unpuriﬁed
plasma or serum samples. A prerequisite for the in-
corporation of EV analysis into robust clinical assays
is the discovery and validation of relevant diagnostic
or prognostic EV targets. Currently, thousands of
EV-related proteins and RNA components have been
identiﬁed by proteomic and transcriptomic ap-
proaches.117 In the discovery process, various cell
lines have been extensively used.7,49,71 Even if cell
lines are only an approximation of the in vivo con-
ditions, they serve as useful model systems and
encompass a relevant source of cell surface–expressed
biomarkers and intracellular proteins and RNAs,
relating to cancer in particular. These in vitro model
systems are consequently valuable in the matter of
identifying which proteins and potential biomarkers
are conveyed to the EVs. As an example, this strategy
was adopted to identify the protein Claudin as an EV-
expressed biomarker for ovarian cancer. Likewise, the
model systems of cell lines have a great potential to
elucidate the biogenesis of EVs and their subsequent
inﬂuence on the recipient cells. This ﬁnding has been
reported in a study in which a mast cell line was
exposed to oxidative stress and the subsequent cell-
derived EVs revealed a changed RNA proﬁle com-
pared with those derived from cells grown under
normal conditions. This study additionally clariﬁed
that the stress-derived EVs were able to affect non-
stressed cells to become more resistant to the oxidative
stress.32 Nonetheless, the use of cell lines and their
autologous production of EVs must be carefully
interpreted. Cell lines are kept in a closed and
controlled system, mainly as monocultures, and will
therefore only receive and respond to the signals
speciﬁcally applied to them. Because the cells receive
no signals or EVs from their original surrounding
environment, they will most likely merely auto-
communicate. Therefore, cell lines will only partly
reﬂect the authenticity of the biogenesis of the EVs. In
the biomarker discovery, the use of mass spectrometryJune 2014(MS) has for at least 2 decades been essential for the
proteomics-driven research of EVs and is the only
technique available that allows EV characterization
from all common clinical biospecimens, including
serum, plasma, urine, synovial ﬂuid, ascites, and feces.
Accordingly, the identiﬁcation of several important EV
protein markers has been facilitated by MS.118 The use
of MS has also provided information about aspects of
EV biogenesis along with possible pathologic functions
of these vesicles.117 Currently, technical methods for
targeted MS platforms are being applied in clinical
assays and include multiple reaction monitoring and
selected reaction monitoring. These methods enable MS
as a high-throughput technique to perform rapid analy-
ses of EV proteins, which could also be used in a
diagnostic fashion and not exclusively in the discovery
phase for EV biomarkers. Nonetheless, the development
of standardizations for EV analysis along with a con-
tinued effort to unravel all aspects of EV proteins and
RNA will improve the understanding of the molecular
mechanisms and biological functions of EVs. Despite
being in its infancy, the ﬁeld of EV research has un-
doubtedly received an enormous interest. Consequently,
numerous initiatives have been implemented in the EV
society, including several databases (ExoCarta,119
EVpedia,120 Vesiclepedia,121 and miRandola122), con-
ferences (International Society for Extracellular Vesicles
conference on microvesiculation and disease), and a
dedicated journal (Journal of Extracellular Vesicles).123
FUTURE CLINICAL PERSPECTIVES
The apparent role of EVs in a vast number of bio-
logical processes, along with many of their intriguing
features, forms the basis of extending EV analysis
beyond basic research and into a clinical and ther-
apeutic context. Despite being a relatively new ﬁeld,
the potential and versatility of EV analysis are sup-
ported by an increasing number of publications. The
applications of this type of analysis include the areas of
diagnostics and prognostics, as well as drug therapy,
regenerative medicine, and vaccines. For the purpose
of diagnosis and prognosis, the use of EVs seems
particularly promising because these vesicles contain a
plethora of clinically relevant molecules, such as
proteins and RNA from the parent cell. Thereby, the
miRNA and protein patterns, which are unique for a
speciﬁc pathologic condition, can be used. The analysis
of EVs could accordingly be incorporated as a screen-
ing tool and applied to conﬁrm a diagnosis.841
Clinical TherapeuticsFurthermore, EV analysis has the potential to become
an element in treatment surveillance and companion
diagnostics, resulting in a patient-optimized treatment.
Related to therapeutics, EVs have been proposed as a
new type of drug delivery system. Such a system involves
engineered EVs loaded with a therapeutic cargo and
expressing ligands, which target a particular tissue or cell
type. The inherent protection of the cargo and tailored
cellular targeting simultaneously enhance the solubility,
stability, and speciﬁcity of the therapeutic agent. In
another approach, the EVs constitute the therapeutic
target, and the aim is to inhibit their release or to
perform a systemic depletion. In terms of regenerative
capabilities, EVs from stem cells have clinical poten-
tial.124 The EVs accordingly constitute a cell-free ap-
proach, which mediates many of the regenerative
properties from the stem cells. This circumvents several
issues related to stem cell transplantations, consequently
making handling and storage easier and increasing the
stability. This cell-free approach has also been adapted
in the ﬁeld of vaccines and immunotherapy. Particularly
in relation to cancer, EVs have been used as potent
inducers of antitumor responses.125,126 In addition,
several Phase I and Phase II studies have been initiated,
almost exclusively focusing on vaccination with autolo-
gous exosomes.8 The results of these studies indicate a
promising future for the use of EV-based treatment. The
abovementioned examples of the clinical use of EV
analysis clearly indicate its feasibility. In line with the
scope of this review, the potential of using EV analysis of
a simple blood sample seems encouraging, and this is
particularly pronounced in relation to diagnostics. De-
spite the extensive amount of information, which is
possible to obtain from a single blood sample, this
complexity is at the same time a challenge that compli-
cates EV analysis. Nonetheless, advances and continued
research within the ﬁeld allow for the development and
improvement of techniques and standard protocols,
which seek to meet these challenges. The increased
understanding of this may lead to a paradigm shift,
particularly related to immune regulation and cellular
communication in cancer. Taken together, technology
and biology will inevitably pave the way for the future
use of EV analysis in many clinical applications.
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